How many insider trades does FilingIQ track for AGMB?

FilingIQ tracks 7 Form 4 insider transactions for AGMB (AgomAb Therapeutics NV), covering filings from Oct 7, 2026 onwards. 7 of those are dated within the last 90 days.

Are AGMB insiders net buyers or net sellers?

Across the full Form 4 history for AGMB, 7 transactions (100%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does AGMB insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.

What sector is AGMB in?

AgomAb Therapeutics NV (AGMB) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $433.38M.

AGMB insider trading

NasdaqGS Healthcare

AgomAb Therapeutics NV: insider trade history from SEC Form 4 filings.

Total Form 4 trades

Last 90 days

Buys / sells

100% / 0%

Market cap

$433.38M

About AgomAb Therapeutics NV

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.

Company website: www.agomab.com

AGMB insider activity at a glance

FilingIQ tracks 7 insider transactions for AGMB in filings since Oct 7, 2026. The most recent transaction is dated Oct 6, 2026.

Across the full history, 7 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on AGMB insider trades is 71.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live AGMB trades on FilingIQ Raw filings on SEC EDGAR

Latest AGMB Form 4 filings

Knotnerus Tim Jasper Chief Executive Officer

P Oct 7, 2026

Kemula Pierre Thadee Victor Chief Financial Officer

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 837

UNITED THERAPEUTICS Corp

BLLN 139

BillionToOne, Inc.

TMO 130

THERMO FISHER SCIENTIFIC INC.

NTRA 129

Natera, Inc.

ATTO 123

Attovia Therapeutics, Inc.

ONC 122

BeOne Medicines Ltd.

CORT 110

CORCEPT THERAPEUTICS INC

CSTL 104

CASTLE BIOSCIENCES INC

Top insiders trading AGMB

Knotnerus Tim Jasper

2 trades · score 73.5

Kemula Pierre Thadee Victor

3 trades · score 72.7

Frequently asked

How many insider trades does FilingIQ track for AGMB?: FilingIQ tracks 7 Form 4 insider transactions for AGMB (AgomAb Therapeutics NV), covering filings from Oct 7, 2026 onwards. 7 of those are dated within the last 90 days.
Are AGMB insiders net buyers or net sellers?: Across the full Form 4 history for AGMB, 7 transactions (100%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does AGMB insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
What sector is AGMB in?: AgomAb Therapeutics NV (AGMB) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $433.38M.

Methodology & sources

Every AGMB insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.